期刊文献+

阿司匹林抵抗在脑梗死二级预防中与血管事件的关系 被引量:12

Relationship between aspirin resistance and vascular events for secondary prevention of cerebral infarction
暂未订购
导出
摘要 目的探讨阿司匹林抵抗在脑梗死二级预防中与血管事件的关系。方法选择脑梗死患者200例为研究对象,患者入院后就口服阿司匹林治疗,服用1周后通过检测血小板聚集率检测患者是否出现阿司匹林抵抗,并对患者进行随访,观察患者脑梗死复发以及其他血管时间发生率,分析阿司匹林抵抗与血管事件发生的相关性。结果单因素分析结果显示,女性、低密度脂蛋白(LDL)升高、糖尿病是发生阿司匹林抵抗的预测因素(P<0.05)。糖尿病、LDL升高是阿司匹林抵抗的危险因素,糖尿病、阿司匹林抵抗、动脉硬化血栓型梗死是血管事件的危险因素(P<0.05或P<0.01)。结论阿司匹林抵抗在脑梗死二级预防中是血管事件的危险因素。 Objective To discuss the relationship between aspirin resistance and vascular events for secondary prevention of cerebral infarction. Methods Selected 200 cases with cerebral infarction who were treated by aspirin. Aspirin resistance was detected at 7 days after treated. Relationship between aspirin resistance and vascular events for sec- ondary prevention of cerebral infarction was analyzed. Results Single factor analysis showed that female, high level of LDL, diabetes mellitus were risk factors of aspirin resistance (P 〈 0.05). Multiple-factor analysis showed that high level of LDL, diabetes mellitus were risk factors of aspirin resistance, and diabetes mellitus, aspirin resistance, arteriosclero- sis thrombosis infarction were risk factors of vascular events (P 〈 0.05 or P〈0.01). Conclusion Aspirin resistance is risk factor of vascular events in secondary prevention of cerebral infarction.
作者 郜晓飞
出处 《中国现代医生》 2014年第3期34-36,共3页 China Modern Doctor
关键词 阿司匹林 脑梗死 抵抗 二级预防 血管事件 Aspirin Cerebral infarction Resistance Secondary prevention Vascular events
  • 相关文献

参考文献6

二级参考文献90

  • 1Pulcinelli FM, Biasucci LM, Riondino S, et al. COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment[J]. Eur Heart J, 2009, 30(10).. 1279-1286.
  • 2Watala C, Colanskij C, Waczulikova L, et al. High glucose contributes to aspirin insensitivity in streptozotocin-diabetic rats: a multiparametric aggregation study[J], Blood Coagul Fibrinolysis, 2006, 17(2): 113-124.
  • 3Zczeklik A, Musia J, Undas A, et al. Aspirin resistance[J]. J Yhromb Haemost, 2005, 3(8): 1655-1662.
  • 4Horiuchi H. Recent advance in antiplatelet therapy: the meehanisms evidence and approach to the problems[J]. Ann Med, 2006, 38(3): 162-172.
  • 5Krasopoulos G, Brister S J, Beattie WS, et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis[J]. BMJ, 2008, 336(7637): 195-198.
  • 6Lancaster GI, Srinivasan J, Jain H, et al. Aspirin resistance: an update[J]. Curt Atheroscler Rep, 2009,11 (2): 105-110.
  • 7Cambria-Kiely JA, Gandhi PJ. Possible mechanisms ofaspirin resistance[J]. J Thromb Thrombol, 2002, 13(1): 49-56.
  • 8Zimmermann N, Weber AA, Hoglfeld T. Aspirin "Resistance" [J]. Herz, 2008, 33(4): 270-278.
  • 9Faraday N, Yanek LR, Mathias R, et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1 [J]. Circulation, 2007, 115 (19): 2490-2496.
  • 10Takahashi S, Ushida M, Komine R, et al. Plateletresponsiveness to in vitro aspirin is independent of COX-1 and COX-2 protein levels and polymorphisms[J]. Thromb Res, 2008, 121(4): 509-517.

共引文献21

同被引文献113

引证文献12

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部